<DOC>
	<DOC>NCT02462876</DOC>
	<brief_summary>This study will assess the long term safety and performance of the GORE® VIABAHN® Endoprosthesis for the treatment of patients with Popliteal Artery Aneurysms.</brief_summary>
	<brief_title>Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<criteria>Inclusion to the study requires the patient: 1. Received a GORE® VIABAHN® Endoprosthesis to treat a popliteal artery aneurysm 2. Had a symptomatic aneurysm or asymptomatic aneurysm (≥ 2 cm diameter) of the popliteal artery, or the presence of mural thrombus (&lt; 2 cm) in the popliteal artery; 3. Was 18 years of age or older at the time of the treatment; 4. Had an elective popliteal artery aneurysm procedure; 5. Has provided Informed Consent, personally or through lawful representation as determined by applicable local regulations and state law Prior to or at the time of implant the patient is / has: 1. Bilateral popliteal artery aneurysms with initial treatment on the same day; 2. Thrombotic occlusion of the popliteal artery or PAA; 3. Marfan syndrome or EhlersDanlos syndrome; 4. Unable to tolerate antiplatelet therapy; 5. Thrombophilia requiring long term anticoagulation; 6. Known allergies to the GORE® VIABAHN® Endoprosthesis components; 7. Enrolled in another investigational drug or medical device trial where participation may have affected the outcome or treatment of the subject in the popliteal artery aneurysm study with the GORE® VIABAHN® Endoprosthesis or had previous surgery for the popliteal artery aneurysm in the study limb.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>